CDXS Codexis, Inc.
XNAS
1.28
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CDXS
$1.28
—
Key stats
$1.28
- 52-Week Range
- $0.96 – $2.98
- YTD
- -20.50%
- Straddle Price
- $0.85
- P/C Vol Ratio
- 0.71
- Market Cap
- $0.1B
- Open
- $1.30
- Day Range
- $1.26 – $1.32
- Volume
- 542,506
- Prev Close
- $1.31
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 1.94 |
| Cost of Equity (CAPM) | 15.79% (VRP-adj) |
| WACC | 13.49% |
| Volatility Risk Premium | +197.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -93.2% |
| Book / Price | 27.8% |
| Gross Margin (TTM) | 87.0% |
| FCF Margin (TTM) | -15.7% |
| Debt / Equity | 1.03 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $1.44 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.34 |
| Bollinger Width / SMA20 | 1125.1% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $0B |
Peers used for multiples: GPRO, IOSP, IOVA, MYGN, PACB, PCRX, SYNA
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
99%
20-Day Fair Value
≈ by Nov 23, 2026
$1.29
α +0.9%
rank 79%
conviction
55%
40-Day Fair Value
≈ by Dec 22, 2026
$1.34
α +4.5%
rank 77%
conviction
97%
60-Day Fair Value
≈ by Jan 20, 2027
$1.37
α +7.3%
rank 77%
conviction
99%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 15.2× · 3 peers |
| Peer P/B | $0.79 | 17% | median 2.2× · 5 peers |
| Peer P/S | $1.83 | 17% | median 1.9× · 7 peers |
| Market Anchor (SMA50) | $1.44 | 67% | stability 79% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- INDUSTRIAL ORGANIC CHEMICALS (2860) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 146
- List Date
- 2010-04-22
- CIK
- 0001200375
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- ($0.09) (2 est.)
- Headquarters
- Redwood City, CA
- Homepage
- https://www.codexis.com
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum reve…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 8.68% | -35.80% | 31.69% | -15.71% | -16.20% | -22.98% | -8.39% |
| Feb | -7.53% | -3.72% | -24.92% | 68.48% | -28.81% | -29.86% | -4.39% |
| Mar | -2.51% | 4.99% | -10.58% | -24.30% | -1.65% | 59.80% | 4.29% |
| Apr | -4.61% | -45.04% | -3.69% | -16.50% | -8.37% | 62.07% | -2.69% |
| May | -8.28% | -15.84% | -45.43% | 8.68% | -0.86% | 3.75% | -9.66% |
| Jun | 9.89% | 4.39% | 16.67% | -10.92% | 8.44% | -15.36% | 2.19% |
| Jul | -6.33% | -36.95% | 32.35% | 19.73% | 11.67% | -40.68% | -3.37% |
| Aug | 26.74% | 4.16% | -47.27% | -16.95% | 1.49% | 17.24% | -2.43% |
| Sep | -16.78% | -12.55% | 5.00% | 8.07% | -2.79% | -7.95% | -4.50% |
| Oct | 33.01% | -7.41% | -16.16% | 3.29% | -5.20% | -5.88%* | 0.27% |
| Nov | 3.37% | -4.04% | 42.17% | 30.86% | -23.45% | -- | 9.78% |
| Dec | -7.38% | -17.23% | 23.48% | 1.06% | -1.21% | -- | -0.26% |
| Total | 18.51% | -86.77% | -41.53% | 27.56% | -54.35% | -25.97% | -27.09% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.34
SMA 50: $1.43
SMA 200: $1.83
Current: $1.28
EMA 12: $1.31
EMA 26: $1.35
MACD: -0.0432 | Signal: 0.0002
BEARISH
ADX (14): 35.67
TREND
+DI: 6.41
−DI: 16.22
Momentum Oscillators
RSI (14): 43.78
NEUTRAL
Stoch %K: 35.46
Stoch %D: 30.94
Williams %R: -70.21
Volume & Volatility
BB Upper: $1.44
BB Lower: $1.24
NEUTRAL
OBV: 39,167,733
Vol SMA 20: 823,628
Vol ROC: -3.12%
ATR: $0.09
True Range: $0.06
HV 20: 68.4%
HV 30: 60.9%
HV 60: 62.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall assessment: NEUTRAL with confidence level (6/10) Key drivers and primary risks: * Strong recent news sentiment, particularly positive headlines around product development and strategic agreements * High volatility, which may be driven by the company's beta of 2.22 relative to the market Primary risks: * The company's high beta makes it more susceptible to market fluctuations * Uncertainty surrounding future earnings releases and potential catalysts
Investment thesis: CDXS is a high-volatility stock with mixed technical signals, supported by positive recent news sentiment. The company's beta makes it more attractive for aggressive investors seeking higher returns, but also increases the risk of significant losses.
Recent news sentiment impact: The recent positive news headlines have contributed to an increase in the stock price, which may continue if these trends persist.
Technical Analysis Trend Direction: * Short-term (1-4 weeks): NEUTRAL * Medium-term (1-3 months): BULLISH * Long-term (3-12 months): BEARISH
Support/Resistance Levels: * Key price levels from moving averages: $2.50, $2.57, and $2.02 * Technical patterns: The stock is trading below its SMA 200, which may indicate a potential bounce or breakout
Momentum Signals: * RSI interpretation (neutral): 44.43 (<70, indicating no overbought condition) * MACD signal (bearish crossover): -0.06 / Signal: -0.03 / Histogram: -0.03 * Bollinger Bands position (squeeze): The stock is trading within a tight range
Volume Analysis: * Volume trends: The stock has seen an increase in volume over the past week, which may indicate growing interest from institutional investors * Institutional interest signals: The OBV and volume rate of change indicators suggest that institutions are accumulating shares
News & Sentiment Analysis Recent Headlines Summary: CDXS has received positive news headlines around product development and strategic agreements.
Sentiment Assessment: The aggregate sentiment is POSITIVE, with 4 out of 6 recent headlines contributing to this assessment.
Catalyst Identification: Upcoming earnings releases may serve as a catalyst for the stock price, particularly if the company beats expectations or provides guidance on future growth initiatives.
Market Narrative: The recent positive news and technical signals align with each other, indicating a potential uptrend. However, the high beta and volatility may continue to drive market sentiment.
Risk & Volatility Assessment Beta Interpretation: CDXS has a high beta of 2.22 relative to the market, making it more susceptible to market fluctuations.
Volatility Regime: The stock is currently experiencing high volatility, which may be driven by the company's beta and recent news headlines.
Options Market Signals: * IV rank: 15.7% (low) * Put/call ratio: 0.04 (bullish sentiment)
Downside Protection: Support levels at $2.19 and $2.02 should be monitored for potential downside risk management considerations.
Market Context & Positioning Sector Performance: The specialty enzymes sector has been trending upward, which may support CDXS's performance.
Institutional Activity: The increase in volume and OBV suggests institutional interest in the stock.
Correlation Analysis: CDXS has a moderate correlation of 0.33 with the market, indicating that it may respond to market movements.
Relative Valuation: CDXS is trading within its historical range, which may indicate fair value or potential upside.
Key Levels & Action Items Critical Price Levels: * Support at $2.19 and $2.02 * Resistance at $2.50 and $2.57
Breakout/Breakdown Levels: * Breakout above $2.82 (upper Bollinger Band) or below $1.91 (lower Bollinger Band)
Time-Sensitive Catalysts: Upcoming earnings releases may serve as a catalyst for the stock price.
Risk Management: Stop-loss levels at $2.00 and $2.10 should be considered, with position sizing adjusted accordingly based on risk tolerance.
By analyzing the technical indicators, news headlines, and risk metrics, it is clear that CDXS is a high-volatility stock with mixed signals. The recent positive news sentiment has contributed to an increase in the stock price, but the company's high beta makes it more susceptible to market fluctuations. Investors should consider these factors when deciding on a trading strategy.
Generated
News
All CDXS news →
Earnings History
17 of 17 under expected move
Avg Expected Move
41.87%
Avg Actual Move
5.36%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-05-06 | Pre-Market | 10.31% | 2.65% | 0.26x | Within |
| 2022-02-24 | Pre-Market | 12.66% | 12.02% | 0.95x | Within |
| 2022-07-14 | Pre-Market | 33.15% | 4.74% | 0.14x | Within |
| 2023-02-23 | Pre-Market | 1.82% | 0.18% | 0.10x | Within |
| 2023-05-04 | Pre-Market | 25.92% | 3.42% | 0.13x | Within |
| 2023-07-20 | Pre-Market | 27.19% | 1.46% | 0.05x | Within |
| 2024-01-09 | Pre-Market | 15.68% | 5.92% | 0.38x | Within |
| 2024-02-28 | Pre-Market | 49.88% | 10.36% | 0.21x | Within |
| 2024-08-08 | After-Close | 88.89% | 11.11% | 0.12x | Within |
| 2024-10-31 | After-Close | 73.25% | 11.46% | 0.16x | Within |
| 2025-02-27 | Pre-Market | 38.46% | 5.53% | 0.14x | Within |
| 2025-05-14 | Pre-Market | 22.46% | 3.52% | 0.16x | Within |
| 2025-08-13 | Pre-Market | 19.23% | 6.64% | 0.35x | Within |
| 2025-11-06 | Pre-Market | 25.58% | 5.35% | 0.21x | Within |
| 2026-03-11 | Pre-Market | 34.27% | 2.42% | 0.07x | Within |
| 2026-05-07 | Pre-Market | 34.77% | 3.01% | 0.09x | Within |
| 2026-08-11 | Pre-Market | 198.33% | 1.33% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CDXS Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.85
7-DTE Move: $0.85
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 72
Put Volume: 51
P/C Volume: 0.708
NEUTRAL
Call OI: 75
Put OI: 53
P/C OI: 0.707
Total OI: 128
ATM Options Pricing
ATM Call: $0.38
ATM Put: $0.47
Call %: 29.3%
Put %: 37.1%
Chain Summary
Chain Volume: 203
Chain OI: 1,336
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 48th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
48%
vs own history
GEX tilt
+1.00
OI-weighted, today
Vanna tilt
+0.98
δ-sensitivity to IV
Charm tilt
-0.98
δ-decay vs time
Vanna tilt +0.98: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.98: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 23 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 23 · ATM 161.7% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.85Oct 23
Beta Analysis
Risk Metrics
Beta: 1.7902
Alpha: -57.54%
Correlation: 0.2643
R-Squared: 7.0%
Stock Volatility: 86.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
CDXS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 90,647,500 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$83.84K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $45.43K | 54.18% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $35.71K | 42.59% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $2.71K | 3.23% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
CDXS Insider Trading (Form 4)
Latest: 2026-10-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Georgia Erbez | See Remarks | Sell (S) | −6,335 | $1.36 | -$8.6K | EDGAR |
| 2026-10-14 | Alison Moore | President and CEO | Sell (S) | −6,335 | $1.36 | -$8.6K | EDGAR |
| 2026-06-18 | Cynthia Collins | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | Rahul Singhvi | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | David V Smith | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | Raymond De Vre | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | Stephen George Dilly | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | Esther Martinborough | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | Christos Richards | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-18 | H Stewart Parker | Director | Grant (A) | +66,350 opt | — | EDGAR | |
| 2026-06-11 | Raymond De Vre | Director | Sell (S) | −2,605 | $2.37 | -$6.2K | EDGAR |
| 2026-02-25 | Georgia Erbez | See Remarks | Grant (A) | +316,100 opt | — | EDGAR | |
| 2026-02-25 | Alison Moore | President and CEO | Grant (A) | +993,000 opt | — | EDGAR | |
| 2026-02-25 | Stefan Lutz | Chief Scientific Officer | Sell (S) | −5,862 | $1.13 | -$6.6K | EDGAR |
| 2026-02-09 | Alison Moore | President and CEO | Sell (S) | −3,826 | $1.31 | -$5.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CDXS Insider Holdings
14 insiders · @ $1.28
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Stephen George Dilly | See Remarks | 727,053 | $930.6K | -$151.3K | 11 | 2026-06-18 |
| 2 | Alison Moore | President and CEO | 244,171 | $312.5K | -$29.2K | 12 | 2026-10-14 |
| 3 | David V Smith | Director | 194,275 | $248.7K | -$62.2K | 13 | 2026-06-18 |
| 4 | Opaleye Management Inc. | 10%+ Owner | 179,989 | $230.4K | $11.11M | 28 | 2025-12-15 |
| 5 | Kevin Norrett | Chief Operating Officer | 177,327 | $227.0K | -$61.7K | 6 | 2025-02-07 |
| 6 | H Stewart Parker | Director | 143,583 | $183.8K | $0 | 5 | 2026-06-18 |
| 7 | Dennis P Wolf | Director | 138,951 | $177.9K | -$3.48M | 33 | 2025-11-25 |
| 8 | Rahul Singhvi | Director | 137,052 | $175.4K | $0 | 6 | 2026-06-18 |
| 9 | Stefan Lutz | Chief Scientific Officer | 130,421 | $166.9K | -$17.8K | 3 | 2026-02-25 |
| 10 | Esther Martinborough | Director | 129,036 | $165.2K | $0 | 7 | 2026-06-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CDXS Board & Officers
As of SEC filings through Oct 14, 2026Directors 8
- David V Smith · since Mar 1, 2016
- Stephen George Dilly · since Jun 16, 2020
- Rahul Singhvi · since Sep 28, 2022
- H Stewart Parker · since Dec 16, 2022
- Raymond De Vre · since Nov 7, 2024
- Christos Richards · since Jan 14, 2025
- Cynthia Collins · since Mar 28, 2025
- Alison Moore · listed since Feb 2026
Officers 3
- Alison Moore · President and CEO · listed since Nov 2025
- Georgia Erbez · Chief Financial Officer and Chief Business Officer · listed since Feb 2026
- Stefan Lutz · Chief Scientific Officer · listed since Feb 2026
10% owners 1
- Opaleye Management Inc. (entity) · on file since Sep 2024
Changes in the last 10 years (37)
| Apr 10, 2026 | The company announced the departure of Esther Martinborough from the board in an SEC filing |
| Apr 8, 2026 | The company announced the departure of Dennis P Wolf from the board in an SEC filing |
| Feb 9, 2026 | Stefan Lutz listed as Chief Scientific Officer (previously Cso) in SEC filings |
| Feb 9, 2026 | Georgia Erbez listed as Chief Financial Officer and Chief Business Officer (previously Chief Financial Officer) in SEC filings |
| Feb 9, 2026 | Alison Moore first listed as a director in an SEC filing |
| Nov 17, 2025 | Alison Moore listed as President and CEO (previously Chief Technical Officer) in SEC filings |
| Nov 12, 2025 | Stephen George Dilly no longer listed as President and Chief Executive Officer in SEC filings |
| Nov 7, 2025 | Stefan Lutz became Cso |
| Apr 4, 2025 | The company announced the departure of Byron L Dorgan from the board in an SEC filing |
| Mar 28, 2025 | Cynthia Collins became a director |
| Jan 14, 2025 | Christos Richards became a director |
| Nov 7, 2024 | Raymond De Vre became a director |
| Oct 16, 2024 | The company announced the departure of Sriram Ryali as Chief Financial Officer in an SEC filing |
| Oct 10, 2024 | Alison Moore first listed as Chief Technical Officer in an SEC filing |
| Sep 30, 2024 | The company announced the departure of Alison Moore from the board in an SEC filing |
| Sep 30, 2024 | Georgia Erbez became Chief Financial Officer |
| Sep 19, 2024 | Opaleye Management Inc. first on file as a 10% owner |
| Feb 13, 2024 | The company announced the departure of Jennifer Aaker from the board in an SEC filing |
| Mar 29, 2023 | The company announced the departure of Patrick Y Yang from the board in an SEC filing |
| Jan 23, 2023 | The company announced the departure of Dean Ross Taylor Jr as SVP, Chief Financial Officer in an SEC filing |
| Jan 23, 2023 | Sriram Ryali became Chief Financial Officer |
| Dec 16, 2022 | H Stewart Parker became a director |
| Oct 31, 2022 | Margaret Nell Fitzgerald became Chief Legal and Compliance Officer |
| Oct 3, 2022 | Kevin Norrett became Chief Operating Officer |
| Sep 28, 2022 | Rahul Singhvi became a director |
| Aug 3, 2022 | Stephen George Dilly first listed as President and Chief Executive Officer in an SEC filing |
| Jul 17, 2022 | The company announced the departure of John J Nicols from the board in an SEC filing |
| Jul 17, 2022 | The company announced the departure of John J Nicols as President and CEO in an SEC filing |
| Mar 9, 2021 | Dean Ross Taylor Jr listed as SVP, Chief Financial Officer (previously Chief Financial Officer) in SEC filings |
| Feb 2, 2021 | Esther Martinborough became a director |
| Aug 5, 2020 | Jennifer Aaker became a director |
| Jun 16, 2020 | Stephen George Dilly became a director |
| Jun 16, 2020 | Alison Moore became a director |
| Aug 20, 2019 | Dean Ross Taylor Jr became Chief Financial Officer |
| Sep 18, 2017 | Vivo Ventures Vii, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 18, 2017 | Vivo Ventures VII Affiliates Fund, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 18, 2017 | Vivo Ventures Fund VII, L.P. reported in an SEC filing no longer being a 10% owner |
Not reported recently (9)
- Kevin Norrett · Last reported as Chief Operating Officer in an SEC filing dated Feb 7, 2025
- Margaret Nell Fitzgerald · Last reported as Chief Legal and Compliance Officer in an SEC filing dated Jan 2, 2024
- Bernard J Kelley · Last reported as a director in an SEC filing dated Aug 12, 2021
- Thomas R Baruch · Last reported as a director in an SEC filing dated Jun 16, 2020
- Kathleen Sereda Glaub · Last reported as a director in an SEC filing dated Jun 13, 2019
- Pam P. Cheng · Last reported as a director in an SEC filing dated Jun 13, 2019
- James Lalonde · Last reported as SVP, R&D in an SEC filing dated May 15, 2019
- Gordon Sangster · Last reported as SVP & Chief Financial Officer in an SEC filing dated Mar 22, 2019
- Michael D. Aldridge · Last reported as Senior Vice President, Corporate & Strategic Development in an SEC filing dated May 18, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CDXS Proposed Insider Sales (Form 144)
Latest: 2026-10-13
? Form 144 Guide
Last 30d:
2 filings
· $17K notice value
· Last 90d:
2 filings
· $17K notice value
· 2 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
MOORE ALISON (1, $9K) · Erbez Georgia (1, $9K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-13 | MOORE ALISON | Officer | 6,335 | $8.6K | 2026-10-12 | Morgan Stanley Smith Barney Oper… | — | EDGAR |
| 2026-10-13 | Erbez Georgia | Officer | 6,335 | $8.6K | 2026-10-12 | Morgan Stanley Smith Barney Oper… | — | EDGAR |
| 2026-02-23 | Lutz Stefan | Officer | 5,280 | $6.2K | 2026-02-24 | Morgan Stanley Smith Barney Exec… | — | EDGAR |
| 2026-02-06 | Lutz Stefan | Officer | 2,460 | $3.1K | 2026-02-06 | Morgan Stanley Smith Barney Exec… | — | EDGAR |
| 2026-02-06 | Norrett Kevin | Officer, Former Chief Operating Officer | 3,291 | $4.2K | 2026-02-06 | Morgan Stanley Smith Barney Exec… | — | EDGAR |
| 2026-01-16 | KEVIN NORRETT | Officer | 1,745 | $2.9K | 2026-01-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-01-07 | Norrett Kevin | Officer | 6,123 | $10.4K | 2026-01-07 | Morgan Stanley Smith Barney | — | EDGAR |
| 2025-11-21 | DENNIS P WOLF | Officer | 8,952 | $14.0K | 2025-11-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-10-14 | MOORE ALISON | Officer | 6,239 | $15.6K | 2025-10-13 | Morgan Stanley Smith Barney | — | EDGAR |
| 2025-10-14 | Erbez Georgia | Officer | 6,239 | $15.6K | 2025-10-13 | Morgan Stanley Smith Barney | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
27 ETFs hold CDXS
25 shown · $13.43M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $4.3M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $3.2M | $74.2B | 2026-10-22 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.6M | — | 2026-09-30 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $1.1M | $13.6B | 2026-10-22 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.01% | $1.0M | $10.7B | 2026-10-22 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $823,006 | — | 2026-09-30 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.03% | $403,514 | $1.2B | 2026-10-22 |
| 8 | FESM Fidelity Enhanced Small Cap Core ETF | Nport | 0.01% | $336,189 | — | 2026-06-30 |
| 9 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $169,407 | $13.9B | 2026-10-22 |
| 10 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $132,001 | — | 2026-09-30 |
| 11 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $100,026 | — | 2026-07-31 |
| 12 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.43% | $86,445 | — | 2026-10-24 |
| 13 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $63,105 | — | 2026-10-23 |
| 14 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $22,574 | $20.3B | 2026-10-22 |
| 15 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.00% | $22,144 | — | 2026-09-30 |
| 16 | FEAC Fidelity Enhanced U.S. All-Cap Equity ETF | Nport | 0.05% | $11,799 | — | 2026-06-30 |
| 17 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.01% | $10,737 | — | 2026-10-24 |
| 18 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $9,374 | — | 2026-09-30 |
| 19 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $7,485 | — | 2026-10-23 |
| 20 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.00% | $7,075 | — | 2026-05-31 |
| 21 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $5,741 | — | 2026-10-23 |
| 22 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.01% | $5,597 | — | 2026-10-23 |
| 23 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $5,188 | $3.2B | 2026-10-22 |
| 24 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $3,809 | — | 2026-10-23 |
| 25 | RESM Columbia Research Enhanced Small Cap ETF | Nport | 0.01% | $325 | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.34
TTM Revenue
$77.68M
TTM Net Income
$-30.72M
TTM Op. Cash Flow
$-10.40M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $14.91M | $-12.01M | $-0.13 | $-9.64M |
| Q1 '26 | 2026-03-31 | $15.25M | $-8.70M | $-0.10 | $-13.15M |
| Q4 '25 | 2025-12-31 | $38.91M | $9.60M | $0.12 | $20.09M |
| Q3 '25 | 2025-09-30 | $8.60M | $-19.61M | $-0.22 | $-7.70M |
| Q2 '25 | 2025-06-30 | $15.33M | $-13.27M | $-0.16 | $-17.97M |
| Q1 '25 | 2025-03-31 | $7.54M | $-20.69M | $-0.25 | $-13.80M |
| Q4 '24 | 2024-12-31 | $21.46M | $-10.38M | $-0.11 | $-16.47M |
| Q3 '24 | 2024-09-30 | $12.83M | $-20.64M | $-0.29 | $-12.98M |
| Q2 '24 | 2024-06-30 | $7.98M | $-22.75M | $-0.32 | $-12.17M |
| Q1 '24 | 2024-03-31 | $17.07M | $-11.51M | $-0.16 | $-7.79M |
| Q4 '23 | 2023-12-31 | $26.56M | $-7.19M | $-0.10 | $-11.04M |
| Q3 '23 | 2023-09-30 | $9.28M | $-34.91M | $-0.50 | $-16.30M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.52
P/S
1.49
EV/EBITDA
—
EV/Sales
1.58
ROE
-93.2%
ROA
-25.6%
Div Yield
0.00%
FCF Yield
-8.97%
Debt/Equity
1.03
Current Ratio
—
Market Cap
$116.03M
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.84M
SI % of Float
4.59%
Days to Cover
5.00
Short Vol Ratio
60.0%
Free Float
105.40M
Float %
96.3%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-08-19